Detail akcie Axsome Therapeutics online

Business Summary: Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Axsome Therapeutics Inc revenues increased from $50M to $270.6M. Net loss increased 28% to $239.2M. Revenues reflect Product sales, net increase from $50M to $202.5M. Higher net loss reflects Novel therapies for management of CNS disorders segment loss increase of 29% to $231.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$4.60 to -$5.27.